Pharma channel feed – Endpoints News

Pharma channel feed

Scangos left Biogen in style, taking a final $17.7M compensation package for one last, disappointing year

9 years ago

Way over budget and years late — AstraZeneca’s massive HQ project offers a troubling symbol

9 years ago

Gottlieb tackles speculators, FDA transparency and the R&D gold standard in a last round of queries ahead of confirmation vote

9 years ago

Otsuka gobbles up more global rights for Akebia’s vadadustat, chipping in to a pot now worth $2B-plus

9 years ago

Blitzed by trial failures, OncoMed axes half its staff and retrenches around PhI drugs

9 years ago

With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact

9 years ago

Marathon Pharmaceuticals signals it will wind down after stirring a hornet’s nest with $89,000 Duchenne treatment

9 years ago

Facing a payer backlash over sticker shock, Biogen fields positive data on Spinraza for children 2-12

9 years ago

J&J faces its second rival Remicade knockoff as FDA gives Merck a shot at a $7B franchise

9 years ago

It’s official: Controversial Marathon Pharmaceuticals bows out at PhRMA in wake of price gouging controversy

9 years ago

XBiotech shares crater as CHMP shudders at its application to sell Xilonix

9 years ago

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from Novartis, Eli Lilly

9 years ago

Vernalis shares slide after FDA turn thumbs down on their latest XR cold med

9 years ago

The list of the top 10 most expensive drugs on the planet will soon have a new opening

9 years ago

Is Tesaro playing a pricing game with Zejula? Not at all, says the CEO. And here's why

9 years ago

That turnaround on new FDA drug approvals? We’re right on schedule

9 years ago

Verily joins up with Duke, Stanford to enlist an army of consumers to put its next-gen sensor tech to the test — and in the public eye

9 years ago

Novartis ties up with the virtual biotech Parvus to try a new approach on Type 1 diabetes

9 years ago

Report: Hanmi’s failure to report patient death in olmutinib study broke South Korea’s medical laws

9 years ago

The UK isn't giving up on keeping the European Medicines Agency's HQ in London without a fight

9 years ago

Scoop: Juno recruits Sunil Agarwal as R&D chief, opening a Bay Area facility in research revamp

9 years ago

In a stunning setback, FDA spurns Eli Lilly’s marketing application for baricitinib, demands more data

9 years ago

New CEOs at Axovant, Destiny and Organovo mark a busy week for the biotech jobs scene

9 years ago

We don’t know when (exactly) Lilly will announce the FDA’s baricitinib decision, but watch out for the looming pricing squabble

9 years ago

First page Previous page 325 326 327328329 330 331 Next page Last page